Arcutis Biotherapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Arcutis Biotherapeutics, Inc. (ARQT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ARQT insiders buying or selling?
In the last 12 months, Arcutis Biotherapeutics, Inc. insiders reported 0 open-market purchases ($0) and 54 sales ($16.2M) — net selling of $16.2M. Since February 2020, Trabud has recorded 260 Form 4 filings for ARQT: 20 buys ($71.6M) and 240 sells ($61.2M).
Source: SEC EDGAR Form 4
What stands out
- No Arcutis Biotherapeutics, Inc. insider made an open-market purchase in the last 12 months; the 54 reported open-market sales totaled $16.2M.
Key Statistics (February 2020 – Sep 18, 2026)
Total Form 4 filings
260
SEC EDGAR
Insider filers
24
Insider buys (20)
$71.6M
Insider sells (240)
$61.2M
Insider sentiment
Net buyingNet insider flow of $10.5M in net buying since February 2020, and $16.2M in net selling over the last 12 months.
Recent ARQT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 3.7K | $25.00 | $91.9K | SEC ↗ |
| Sep 17, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $24.18 | $114.4K | SEC ↗ |
| Sep 10, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 10.0K | $25.03 | $250.0K | SEC ↗ |
| Aug 28, 2026 | Terrie Curran | Director | Sale | 38.2K | $25.03 | $956.1K | SEC ↗ |
| Aug 24, 2026 | Terrie Curran | Director | Sale | 1.1K | $26.04 | $27.9K | SEC ↗ |
| Aug 21, 2026 | Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | Sale | 1.7K | $27.00 | $45.8K | SEC ↗ |
| Aug 19, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $26.18 | $123.8K | SEC ↗ |
| Aug 14, 2026 | Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | Sale | 15.0K | $26.33 | $394.9K | SEC ↗ |
| Aug 6, 2026 | Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | Sale | 955 | $26.12 | $24.9K | SEC ↗ |
| Aug 6, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 1.2K | $26.12 | $32.1K | SEC ↗ |
| Aug 6, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 4.4K | $26.12 | $114.3K | SEC ↗ |
| Jul 17, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $26.91 | $127.3K | SEC ↗ |
| Jun 18, 2026 | Sue-Jean Lin | Director | Sale | 4.9K | $24.38 | $120.6K | SEC ↗ |
| Jun 18, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $24.58 | $116.3K | SEC ↗ |
| May 13, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 435 | $21.05 | $9.2K | SEC ↗ |
| May 13, 2026 | Patrick Burnett | Reporting Person's Title: EVP, Chief Medical Officer | Sale | 222 | $21.05 | $4.7K | SEC ↗ |
| May 6, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 8.3K | $23.31 | $192.4K | SEC ↗ |
| May 6, 2026 | Patrick Burnett | Reporting Person's Title: EVP, Chief Medical Officer | Sale | 684 | $23.61 | $16.1K | SEC ↗ |
| May 6, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 1.3K | $23.61 | $31.7K | SEC ↗ |
| May 6, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 3.2K | $23.61 | $74.9K | SEC ↗ |
| May 6, 2026 | Howard G. Welgus | Director | Sale | 7.1K | $22.99 | $164.2K | SEC ↗ |
| Apr 3, 2026 | Howard G. Welgus | Director | Sale | 10.0K | $23.88 | $238.8K | SEC ↗ |
| Mar 4, 2026 | Keith R Leonard | Director | Sale | 39.3K | $25.39 | $997.2K | SEC ↗ |
| Mar 4, 2026 | Howard G. Welgus | Director | Sale | 10.0K | $25.65 | $256.5K | SEC ↗ |
| Mar 4, 2026 | Larry Todd Edwards | Reporting Person's title: EVP, Chief Commercial Officer | Sale | 3.7K | $25.18 | $92.8K | SEC ↗ |
Showing the 25 most recent of 260 Form 4 filings for Arcutis Biotherapeutics, Inc..
Most active ARQT insiders
- Todd Watanabe59 filings
- Howard G. Welgus57 filings
- Patrick Burnett33 filings
- Masaru Matsuda27 filings
- David W Osborne9 filings
Ask anything about ARQT insider activity
Use Trabud's AI agent to query Arcutis Biotherapeutics, Inc.'s Form 4 history in plain English — "Show me ARQT CEO purchases this year" or compare it against any other ticker.
Open the AI agentARQT insider trading FAQ
Are Arcutis Biotherapeutics, Inc. insiders buying or selling?
In the last 12 months, Arcutis Biotherapeutics, Inc. insiders reported 0 open-market purchases ($0) and 54 sales ($16.2M) — net selling of $16.2M. Since February 2020, Trabud has recorded 260 Form 4 filings for ARQT: 20 buys ($71.6M) and 240 sells ($61.2M). Over the full record that is net buying of $10.5M.
How many insiders trade ARQT stock?
24 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Arcutis Biotherapeutics, Inc.. The most recent filing was accepted on Sep 18, 2026.
Where does Trabud get ARQT insider trading data?
All ARQT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.